As of Oct 23
| -0.06 / -1.79%|
The 2 analysts offering 12-month price forecasts for Caladrius Biosciences Inc have a median target of 6.75, with a high estimate of 7.00 and a low estimate of 6.50. The median estimate represents a +105.17% increase from the last price of 3.29.
The current consensus among 2 polled investment analysts is to Buy stock in Caladrius Biosciences Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.